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Abstract 
Neuroendocrine tumors are tumors 
derived from the cells of the 
neuroendocrine system. The majority of 
metastases of neuroendocrine tumors occur 
in liver, lungs and bone. The brain is an 
uncommon site of metastasize for this type 
of tumor. The authors of this paper present 
a case of brain metastases of 
neuroendocrine tumor with undetermined 
primary location. The patient, a 35 years-
old man, was admitted in our clinic with 
headache, nausea, vomiting and a mild right 
facial paresis. Head CT scan and cerebral 
MRI identified two lesions: one larger 
lesion with mixed solid and cystic 
components located in the left basal ganglia 
and thalamus and a second cystic lesion 
located deep in the right parietal lobe. All 
complementary investigations (including 
thoracic CT scan and whole-body MRI) 
failed to reveal the primary tumor location. 
Due to the high vital-risks associated with 
the open surgical procedure, the patient and 
his family chose the less invasive procedure 
of stereotactic biopsy. Postoperatively the 
patient had no additional neurologic 
deficits, presenting only the initial mild 
right central facial paresis. The result of 
immunohistochemistry examination was 
cerebral metastases of neuroendocrine 
tumor. The patient was directed to the 
Institute of Oncology Fundeni for further 
investigations and therapeutically 
management. In conclusion, even if these 
are rare tumors which rarely metastasize in 
the brain, the neurosurgeons should take in 
consideration this pathology when they 
examine a patient with multiple cerebral 
lesions with unknown location of primary 
tumor. 
Key words: neuroendocrine tumors, 
stereotactic biopsy, immunohistochemistry. 
Introduction 
Neuroendocrine tumors are tumors 
derived from the cells of the 
neuroendocrine system which have the 
primary role of synthesizing biogenic 
amines and peptidic hormones (20). The 
cells of neuroendocrine system could be 
classified in two distinct cells populations: 
1. Nerve cells – located either in central 
nervous system or peripheral nerve 
ganglions, which belong to the peptidergic 
and adrenergic cells of autonomous 
nervous system and 2. Epithelial cells – in 
the parenchyma of endocrine glands, but 
many cells are also disseminated 
throughout the mucosa of respirator and 
gastrointestinal tract.  Neuroendocrine 
nerve cells rarely undergo hyperplasia or 
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neoplasic transformation, but in epithelial 
neuroendocrine cells, the neoplasic 
transformation can occur both in endocrine 
glands and at the level of teguments and 
mucosa (17). World Health Organization 
(WHO) classifies the neuroendocrine 
tumors according to their proliferation 
index (PI) into the following groups: well 
differentiated endocrine tumors (PI<2%), 
well differentiated endocrine carcinomas 
(2%≤PI<15%), poor differentiated 
endocrine carcinomas (PI≥15%) (12). 
According to the cell type and the peptides 
synthesized by the cells, there are two main 
groups of endocrine tumors: pancreatic and 
carcinoid neuroendocrine tumors (8). The 
carcinoid neuroendocrine tumors are: 
tymic carcinoid, bronchial carcinoid, gastric 
carcinoid, duodenal and pancreatic 
carcinoid, carcinoid of the jejunum, ileum 
and proximal colon, distal colon and 
rectum (18). Neuroendocrine tumors 
usually metastasize in liver, lungs and bone 
(10). The brain is an uncommon site of 
metastasize for this type of tumor. The 
authors of this paper present a case of rare 
cerebral metastases of neuroendocrine 
tumor with undetermined primary location.  
Case presentation 
The authors present a case of 35 years-
old man without significant associated 
pathology who was admitted in our clinic 
with headache, nausea, vomiting and a mild 
right facial paresis with acute onset. The 
neurological exam at presentation 
demonstrated Romberg’s sign positive and a 
mild right central-type facial paresis. Head 
CT scan showed two enhanced hyperdense 
lesions. One larger lesion located in left 
thalamus and basal ganglia with a mild mass 
effect on the third and left lateral ventricle. 
The smaller lesion was located 
paraventricular, deep-seated in the right 
parietal lobe. The cerebral MRI showed 
mixed solid and cystic components of the 
larger lesion with gadolinium enhancement 
and mass effect on the ventricular system. 
The smaller lesion showed only a cystic 
component without solid nodule. Because 
of the presence of multiple cerebral lesions, 
we hypothesized the diagnosis of cerebral 
metastases and recommended the whole-
body MRI which failed to identify the 
primary lesions. The abdominal echography 
and thoracic CT scan were also negative. 
Patient refused to undergo the more 
invasive investigations like gastro- and 
colonoscopy. Therefore, all the mentioned 
investigation failed to reveal the primary 
source. Due to the high vital-risks 
associated with the open surgical procedure, 
the patient and his family chose the less 
invasive procedure of stereotactic biopsy. 
The blood tests ruled out any abnormalities 
in the coagulogram or platelet count. The 
corticosteroid therapy (dexamethazone 8 
mg intravenous twice daily) had been 
initiated before the surgical procedure. For 
this procedure, we used the Leksell 
stereotactic system and the software 
Stereotactic Planning System (SPS), NTPS 
8.2. The coordinate frame was applied 
using local anesthetics lidocaine 1%. The 
MRI 1,5 Tesla (Philips Integra) 
(gadolinium-enhanced T1-weighted, 1 mm 
slice thickness and T2-weighted, 2 mm 
slice thickness) was used for scanning the 
fiducial system. For operatory procedure, 
we employed general anesthesia. We chose 
to target the larger lesion located in left 
thalamus and insula, because this lesion had 
both cystic and solid components even if it 
had a mass effect on the third and left 
lateral ventricle. 
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Figure 1   Image of the preoperative planning of the biopsy procedure.  
The target is at the gadolinium enhanced periphery of the larger lesion 
 
 
Figure 2   Volumetric assessment of the cerebral lesions. Multiplanar and 3D images of the trajectory 
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Figure 3   Postoperative cerebral CT scan. No sign of hemorrhage at the biopsy site 
 
A small incision (2 cm long) and a single 
burr hole located at the left pre-coronal 
frontal level have been performed. We 
chose multiple targets located along the 
shortest trajectory which avoids eloquent 
areas and vessels. The first target was at the 
gadolinium enhanced periphery of the 
lesion (Figure1, Figure 2). Five tumor 
samples of millimeter size were obtained 
using the side-cutting Sedan I biopsy 
needle, which were sent to the department 
of histopathology. Then we advanced 12 
mm along the trajectory inside the tumor 
cyst and evacuated approximately 15 ml of a 
xantocromic appearance fluid. 
Postoperatively the patient had no 
additional neurologic deficits, presenting 
only the initial mild right central facial 
paresis. The initial symptoms of intracranial 
hypertension remitted after medical 
therapy. The patient received 
corticotherapy, prophylactic antibiotics and 
prophylactic anticonvulsivant therapy until 
he was discharged from our department at 
four days after stereotactic procedure. The 
postoperative CT scan showed no sign of 
hemorrhage at the biopsy site and almost 
complet evacuation of the content of the 
tumoral cyst (Figure 3). 
The histopathological result 
(hematoxylin & eosine staining) revealed 
the diagnosis of metastasis of microcellular 
carcinoma and recommended the 
immunohistochemistry test for a more 
accurate diagnosis. The result of 
immunohistochemistry examination was 
cerebral metastases of a neuroendocrine 
tumor with an undetermined primary 
location. The patient was directed to the 
Institute of Oncology Fundeni for further 
investigations and therapeutically 
management. 
Discussions 
The majority of metastases of 
neuroendocrine tumors occur in the liver, 
lungs and bone. Brain location of 
metastases of neuroendocrine tumor is rare 
(10). Of all brain metastases, only 1.3–1.4% 
have origin in a neuroendocrine tumor (9). 
In patients with neuroendocrine tumors, 
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the incidence of brain metastases is 
estimated to be 1.5–5% (6). Of all type, 
bronchopulmonary neuroendocrine tumors 
appear to be the most frequent source of 
cerebral metastases (1). Thus, in the largest 
series of brain metastases the primary 
tumor was located in the bronchi or lungs 
in 45 and 71% of the patients, respectively 
(14). In our case, the head CT scan and 
cerebral MRI identified two lesions. One 
larger lesion with mixed solid and cystic 
components located in the left basal ganglia 
and thalamus and a second cystic lesion 
located deep in the right parietal lobe. The 
presence of two cerebral lesions raised the 
following possible diagnosis: multiple 
metastases, multiple brain abscesses or 
multicentric gliomas. In order to confirm 
the diagnosis of cerebral metastases, we 
investigated the patient for common tumor 
primary location like lung, prostate, 
digestive tract, with thoracic CT scan and 
whole-body MRI. The patient refused the 
more invasive investigation procedures like 
gastro- and colonoscopy. All investigation 
failed to reveal the primary source. 
Therefore, obtaining tissue samples from 
cerebral lesions became mandatory for the 
therapeutically management of the patient. 
There were two surgical options in this 
case. One was the open surgical procedure, 
which had the advantage of performing a 
large resection of the tumor, besides 
obtaining tissue samples. The main 
limitation of the open procedure was that it 
would have been impossible to remove 
both lesions in one surgical session. 
Moreover, the patient and his caregivers 
refused the open surgical procedure 
because of the risk of the postoperative 
neurological deficits. Therefore, the only 
procedure which could have obtained a 
tissue sample with low risks for the patient 
was the stereotactic biopsy. The availability 
of image-based stereotactic surgery opened 
new perspectives for the management of 
brain tumors. The most common 
stereotactic procedure became biopsy (4) 
and one main indication of this procedure 
was the biopsy of cerebral metastases with 
unknown primary sources (5). The full 
protocol of stereotactic biopsy was 
described by the authors elsewhere (2). 
Choosing the target is one of the most 
important parts of the stereotactic 
procedure because this will aid in obtaining 
the most representative tissue samples for 
diagnosis. In this case, there were two 
lesions accessible for stereotactic biopsy. 
One larger lesion located in the dominant 
hemisphere with mass effect on the 
ventricular system and a second lesion 
located paraventricular in the right parietal 
lobe. Choosing the target inside the smaller 
lesion located on the right side would have 
been more safely for the patient. But that 
lesion was cystic and the major risk would 
have been to not obtain a representative 
tissue for diagnosis. Therefore, we had to 
target the larger lesion located in left 
thalamus and insula, even if that lesion had 
a mass effect on the third and left lateral 
ventricle. The result of the classic 
histopathologic was metastases of 
microcellular carcinoma. However, in this 
case, the immunohistochemistry 
established the final diagnosis of cerebral 
metastases of neuroendocrine tumors. The 
abdominal echography, thoracic CT scan 
and whole-body MRI were not able to 
reveal the primary source of tumors. On 
the other hand, the gold standard in the 
diagnosis of neuroendocrine tumors and 
their metastases is the scintigraphy of 
somatostatin receptors (Octreoscan) (13; 
15). This is a “whole body” scan, which 
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may help not only in diagnosis but also in 
stadialization of the disease if the tumors 
expressed somatostatin receptors. Another 
important investigation is positron emission 
tomography (PET) (3). The most used 
tracer is F18 - deoxiglucoza (FDG-PET), 
but the well differentiated neuroendocrine 
tumors do not uptake the FDG very well 
and 68Ga-DOTATATE-PET could be 
better for detecting pulmonary neuro-
endocrine tumors (7). PET is able to detect 
smaller tumors compared with CT or MRI. 
When the patient is scanned using 
scintigraphy of somatostatin receptors and 
PET, the primary tumor is identified in the 
most cases. Thus, according to one review 
of over 35,000 patients diagnosed with 
neuroendocrine tumors over a 31-year 
period a primary site could not be found or 
classified in only 13 percent (19).  It is 
important to mention that only a minority 
of patients present with brain metastases as 
the initial symptom of their disease or as 
the only metastatic site (9; 11; 16). Both the 
scintigraphy of somatostatin receptors and 
PET were not available in our clinic. 
Therefore, we directed the patient to the 
Institute of Oncology Fundeni for further 
investigations and oncological treatment.   
Conclusions 
The authors present a rare case of 
cerebral metastases of neuroendocrine 
tumor with unknown location of the 
primary lesion. Neuroendocrine tumors 
could be very small lesions located 
anywhere along the respirator or digestive 
tract and even the most advanced 
investigation tools like whole-body MRI 
and PET could fail to reveal the primary 
location of the tumor. Even if these are rare 
tumors which rarely metastasize in the 
brain, the neurosurgeon should take in 
consideration this pathology as a possible 
diagnostic when he or she is confronted 
with a case of multiple cerebral lesions with 
unknown location of primary tumor. 
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